Evidence map›Paper›PMID 33816695›Full record

ArticleAmerican journal of clinical and experimental urology2021

Immunochemical expression of fibroblast growth factor and its receptors in primary tumor cells of renal cell carcinoma.

Maria Volkova, Ilya Tsimafeyeu, Anna Olshanskaya, Yulia Khochenkova, Eliso Solomko, Saida Ashuba, Vsevolod Matveev, Dmitry Khochenkov

Open access · greenAbstract read
In one paragraph

Article in American journal of clinical and experimental urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma.International journal of urology : official journal of the Japanese Urological Association · 2022
    Review
  7. [Expression and significance of fibroblast growth factor receptor 2 in clear cell renal cell carcinoma].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Maria VolkovaN.N. Blokhin National Medical Research Center for Oncology Moscow, Russian Federation.
Ilya TsimafeyeuInstitute of Oncology, Hadassah Moscow Moscow, Russian Federation.
Anna OlshanskayaN.N. Blokhin National Medical Research Center for Oncology Moscow, Russian Federation.
Yulia KhochenkovaN.N. Blokhin National Medical Research Center for Oncology Moscow, Russian Federation.
Eliso SolomkoN.N. Blokhin National Medical Research Center for Oncology Moscow, Russian Federation.
Saida AshubaN.N. Blokhin National Medical Research Center for Oncology Moscow, Russian Federation.
Vsevolod MatveevN.N. Blokhin National Medical Research Center for Oncology Moscow, Russian Federation.
Dmitry KhochenkovN.N. Blokhin National Medical Research Center for Oncology Moscow, Russian Federation.
Russian Cancer Research Center NN Blokhin · RUTogliatti State University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is the evidence of the role of the fibroblast growth factor and its receptors (FGF/FGFR) signaling pathway in tumorogenesis of renal cell carcinoma (RCC). We conducted a study aimed at evaluating of FGF2, FGFR1, and FGFR2 expression in primary tumor cells and assessing of these molecules expression levels effect on the characteristics of the tumor process and prognosis of patients with RCC.

methodsExpression of FGF2, FGFR1, and FGFR2 was investigated in 65 primary RCC specimens by immuhistochemical staining using the appropriate antibodies. Expression levels were evaluated by the semi-quantitative method. A search for correlations of expression levels of investigated growth factors and receptors with RCC features and patients outcomes was performed.

resultsCytoplasm and membrane expression of FGF2, FGFR1, and FGFR2 was found in the primary tumor cells of RCC patients. FGF2 staining was detected in 60.0% of cases (44.2 ± 5.4 HS). It was noted higher frequency and intensity of FGFR2 expression (66.2%; 46.6 ± 6.3 HS) comparing with FGFR1 (32.3%; 7.5 ± 2.2 HS). The correlation was revealed between the investigated markers overexpression and Fuhrman grade G3-4, as well as features of advanced RCC (paranephric fat tumor invasion, venous wall tumor invasion, adrenal and liver metastases). FGFR2 overexpression showed negative influence on cancer-specific survival in univariate analysis, however, lost its predictive value in multivariable analysis.

conclusionExpression of FGF2 and its receptors was found on the surface and in the cytoplasm of RCC primary tumor cells and needs following investigations.

Indexed as

expressionfibroblast growth factorfibroblast growth factor receptorprimary tumorRenal cell carcinomasurvival

Identifiers

PMID33816695
PMCPMC8012831
OpenAlexW3146829913

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.